Equity Profile

EXEL

Exelixis, Inc.

Health CareBiotechnology$13.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.87

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and product demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $13 billion, it plays a significant role in the health care sector, particularly in oncology, where advancements can lead to improved patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q1 2026, Exelixis reported an EPS of $0.87, surpassing expectations by 29.27%. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for its cancer therapies.
Commitment to maintaining strong financial performance.
Plans to explore new market opportunities in oncology.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Exelixis's upcoming earnings, given its strong EPS performance in recent quarters. However, the lack of specific revenue guidance may lead to uncertainty.

Bull Case

If Exelixis continues its trend of beating EPS estimates, it could indicate robust operational efficiency and strong demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or if R&D spending increases without corresponding revenue growth, it could raise concerns about sustainability, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.87

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and product demand.

R&D Spending

N/A

Investment in research and development is vital for biotech firms like Exelixis, as it drives future product pipelines and innovation.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given Exelixis's history of beating EPS estimates, the actual number will be crucial for investor confidence and stock performance.

How much is Exelixis investing in R&D this quarter?

Increased R&D spending could indicate a commitment to innovation, but if it outpaces revenue growth, it may raise concerns about financial sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Exelixis's recent clinical trial successes, which could lead to stronger-than-expected demand for its therapies.

Supporting Evidence

Exelixis has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting expectations of volatility.

Recent trends in oncology suggest increasing demand for innovative cancer treatments, which Exelixis is well-positioned to meet.

Key Risk

If the reported EPS significantly exceeds $0.90, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to maintain profitability against its investment in future growth, making these triggers critical.

Bull Confirmed If

An EPS of $0.90 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.80 could signal potential issues in revenue generation or increased costs.

Pre-Earnings Positioning

Options Market

Implied Move

±14.31%

Historical Avg

±1.1%

In line with history

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations and raises guidance, history suggests a positive stock reaction, potentially around a 1% increase on the first trading day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement, reflecting investor caution.

Miss

A miss on EPS could lead to a decline, with historical patterns suggesting an average drop of around 0.79% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new clinical trials and their expected outcomes.
2Details on revenue growth and product demand in the oncology market.
3Management's perspective on R&D spending and future product pipeline.
4Insights into competitive positioning within the biotechnology sector.
5Any commentary on market conditions affecting sales and growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.87

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and product demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q1 2026, Exelixis reported an EPS of $0.87, surpassing expectations by 29.27%. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for its cancer therapies.
Commitment to maintaining strong financial performance.
Plans to explore new market opportunities in oncology.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Exelixis's upcoming earnings, given its strong EPS performance in recent quarters. However, the lack of specific revenue guidance may lead to uncertainty.

Bull Case

Bear Case

Key Metrics to Watch

Earnings Per Share (EPS)

$0.87

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and product demand.

R&D Spending

N/A

Investment in research and development is vital for biotech firms like Exelixis, as it drives future product pipelines and innovation.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given Exelixis's history of beating EPS estimates, the actual number will be crucial for investor confidence and stock performance.

How much is Exelixis investing in R&D this quarter?

Increased R&D spending could indicate a commitment to innovation, but if it outpaces revenue growth, it may raise concerns about financial sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Exelixis's recent clinical trial successes, which could lead to stronger-than-expected demand for its therapies.

Supporting Evidence

Exelixis has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting expectations of volatility.

Recent trends in oncology suggest increasing demand for innovative cancer treatments, which Exelixis is well-positioned to meet.

Key Risk

If the reported EPS significantly exceeds $0.90, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to maintain profitability against its investment in future growth, making these triggers critical.

Bull Confirmed If

An EPS of $0.90 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.80 could signal potential issues in revenue generation or increased costs.

Pre-Earnings Positioning

Options Market

Implied Move

±14.31%

Historical Avg

±1.1%

In line with history

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations and raises guidance, history suggests a positive stock reaction, potentially around a 1% increase on the first trading day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement, reflecting investor caution.

Miss

A miss on EPS could lead to a decline, with historical patterns suggesting an average drop of around 0.79% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new clinical trials and their expected outcomes.
2Details on revenue growth and product demand in the oncology market.
3Management's perspective on R&D spending and future product pipeline.
4Insights into competitive positioning within the biotechnology sector.
5Any commentary on market conditions affecting sales and growth.